View source for Template:Amphetamine base in marketed amphetamine medications

{{clear}}
{| class="wikitable" style="clear:left; align:left"
|+Amphetamine base in marketed amphetamine medications
! colspan="2" rowspan="3" |drug
! rowspan="3" |formula
! colspan="2" |[[Physics:Molecular mass|molecular mass]]<br />{{#tag:ref|For uniformity, molecular masses were calculated using the Lenntech Molecular Weight Calculator<ref>{{Cite web | title = Molecular Weight Calculator | publisher = Lenntech | url =http://www.lenntech.com/calculators/molecular/molecular-weight-calculator.htm | accessdate = 19 August 2015}}</ref> and were within 0.01g/mol of published pharmaceutical values.| group = "note" }}
! colspan="3" |amphetamine base<br />{{#tag:ref|Amphetamine base percentage = molecular mass<sub>base</sub> / molecular mass<sub>total</sub>. Amphetamine base percentage for Adderall = sum of component percentages / 4.| group = "note" }}
! colspan="2" |amphetamine base<br />in equal doses
! rowspan="3" |doses with<br />equal base<br />content<br />{{#tag:ref|dose = (1 / amphetamine base percentage) &times; scaling factor = (molecular mass<sub>total</sub> / molecular mass<sub>base</sub>) &times; scaling factor. The values in this column were scaled to a 30&nbsp;mg dose of dextroamphetamine sulfate. ''Due to pharmacological differences between these medications (e.g., differences in the release, absorption, conversion, concentration, differing effects of enantiomers, half-life, etc.), the listed values should not be considered equipotent doses.'' | group = "note" }}
|-
! colspan="2" |{{nobold|(g/mol)}}
! colspan="3" |{{nobold|(percent)}}
! colspan="2" |{{nobold|(30&nbsp;mg dose)}}
|-
!total
!base
!total
!dextro-
!levo-
!dextro-
!levo-
|-
| colspan="2" |'''dextroamphetamine sulfate'''<ref name="damph1">{{Cite web | date = March 2014 | title = Dextroamphetamine Sulfate USP | publisher = Mallinckrodt Pharmaceuticals | url =http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491568 | accessdate = 19 August 2015 }}</ref><ref name="damph2">{{Cite web | date = 2015 | title = D-amphetamine sulfate | publisher = Tocris | url =http://www.tocris.com/dispprod.php?ItemId=5305#.VXpspvlViko | accessdate = 19 August 2015}}</ref>
|(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•H<sub>2</sub>SO<sub>4</sub>
|<center>368.49</center>
|<center>270.41</center>
|<center>73.38%</center>
|<center>73.38%</center>
|<center>—</center>
|<center>22.0&nbsp;mg</center>
|<center>—</center>
|<center>30.0&nbsp;mg</center>
|-
! colspan="11" |
|-
| colspan="2" |'''amphetamine sulfate'''<ref name="Amph sulfate mass" />
|(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•H<sub>2</sub>SO<sub>4</sub>
|<center>368.49</center>
|<center>270.41</center>
|<center>73.38%</center>
|<center>36.69%</center>
|<center>36.69%</center>
|<center>11.0&nbsp;mg</center>
|<center>11.0&nbsp;mg</center>
|<center>30.0&nbsp;mg</center>
|-
! colspan="11" |
|-
| colspan="2" |'''Adderall'''
|
|
|
|<center>62.57%</center>
|<center>47.49%</center>
|<center>15.08%</center>
|<center>14.2&nbsp;mg</center>
|<center>4.5&nbsp;mg</center>
|<center>35.2&nbsp;mg</center>
|-
|25%
|dextroamphetamine sulfate<ref name="damph1"/><ref name="damph2"/>
|(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•H<sub>2</sub>SO<sub>4</sub>
|<center>368.49</center>
|<center>270.41</center>
|<center>73.38%</center>
|<center>73.38%</center>
||<center>—</center>
|
|
|
|-
|25%
|amphetamine sulfate<ref name="Amph sulfate mass">{{Cite web | date = March 2014 | title = Amphetamine Sulfate USP | publisher = Mallinckrodt Pharmaceuticals | url =http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491599 | accessdate = 19 August 2015 }}</ref>
|(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•H<sub>2</sub>SO<sub>4</sub>
|<center>368.49</center>
|<center>270.41</center>
|<center>73.38%</center>
|<center>36.69%</center>
|<center>36.69%</center>
|
|
|
|-
|25%
|dextroamphetamine saccharate<ref>{{Cite web | date = March 2014 | title = Dextroamphetamine Saccharate | publisher = Mallinckrodt Pharmaceuticals | url =http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491576 | accessdate = 19 August 2015 }}</ref>
|(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•C<sub>6</sub>H<sub>10</sub>O<sub>8</sub>
|<center>480.55</center>
|<center>270.41</center>
|<center>56.27%</center>
|<center>56.27%</center>
|<center>—</center>
|
|
|
|-
|25%
|amphetamine aspartate monohydrate<ref name="amph2">{{Cite web | date = March 2014 | title = Amphetamine Aspartate | publisher = Mallinckrodt Pharmaceuticals | url =http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491591 | accessdate = 19 August 2015 }}</ref>
|(C<sub>9</sub>H<sub>13</sub>N)•C<sub>4</sub>H<sub>7</sub>NO<sub>4</sub>•H<sub>2</sub>O
|<center>286.32</center>
|<center>135.21</center>
|<center>47.22%</center>
|<center>23.61%</center>
|<center>23.61%</center>
|
|
|
|-
! colspan="11" |
|-
| colspan="2" |'''lisdexamfetamine dimesylate'''{{if pagename|Amphetamine=<ref name=USVyvanselabel/>|Lisdexamfetamine=<ref name=USVyvanselabel/>|other=<ref name=USVyvanselabel>{{cite web | title=Vyvanse Prescribing Information | url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021977s045,208510s001lbl.pdf | pages = 17–21 | website = United States Food and Drug Administration | publisher = Shire US Inc. | accessdate=10 July 2017 | date = May 2017}}</ref>}}
|C<sub>15</sub>H<sub>25</sub>N<sub>3</sub>O•(CH<sub>4</sub>O<sub>3</sub>S)<sub>2</sub>
|<center>455.49</center>
|<center>135.21</center>
|<center>29.68%</center>
|<center>29.68%</center>
|<center>—</center>
|<center>8.9&nbsp;mg</center>
|<center>—</center>
|<center>74.2&nbsp;mg</center>
|-
! colspan="11" |
|-
| colspan="2" |'''amphetamine base suspension'''{{#tag:ref|This product (Dyanavel XR) is an oral [[Chemistry:Suspension|suspension]] (i.e., a drug that is suspended in a liquid and [[Medicine:Oral administration|taken by mouth]]) that contains 2.5&nbsp;mg/mL of amphetamine base.<ref name="Dyanavel" />{{if pagename|Amphetamine=|Dextroamphetamine=|other=&nbsp;The amphetamine base contains dextro- to levo-amphetamine in a ratio of 3.2:1,<ref name="Dyanavel" /> which is approximately the ratio in Adderall.}} The product uses an ion exchange resin to achieve extended release of the amphetamine base.<ref name="Dyanavel" /> | group = "note" }}{{if pagename|Amphetamine=<ref name="Dyanavel" />|Lisdexamfetamine=<ref name="Dyanavel" />|Dextroamphetamine=<ref name="Dyanavel" />|Adderall=<ref name="Dyanavel" />|other=<ref name="Dyanavel">{{cite web | title=Dyanavel XR Prescribing Information | url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208147s003lbl.pdf | publisher= Tris Pharma, Inc. | work=United States Food and Drug Administration | accessdate=4 August 2017 | pages=1–14 | date=May 2017 | quote=DYANAVEL XR contains d-amphetamine and l-amphetamine in a ratio of 3.2 to 1&nbsp;...<br />DOSAGE FORMS AND STRENGTHS<br />Extended-release oral suspension contains 2.5 mg amphetamine base per mL.}}</ref>}}
|C<sub>9</sub>H<sub>13</sub>N
|<center>135.21</center>
|<center>135.21</center>
|<center>100%</center>
|<center>76.19%</center>
|<center>23.81%</center>
|<center>22.9&nbsp;mg</center>
|<center>7.1&nbsp;mg</center>
|<center>22.0&nbsp;mg</center>
|}<noinclude><!--Start of noinclude section-->

<!--Template reflist-->
{{Template reflist|note}}
</noinclude><!--End of noinclude section-->